201 related articles for article (PubMed ID: 34001695)
21. ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus.
Mohammad N; Haimes JD; Mishkin S; Kudlow BA; Leong MY; Chew SH; Koay E; Whitehouse A; Cope N; Ali RH; Köbel M; Stewart CJR; McCluggage WG; Lee CH
Am J Surg Pathol; 2018 Oct; 42(10):1353-1359. PubMed ID: 30015720
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
[TBL] [Abstract][Full Text] [Related]
23. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217.
Kuroda N; Trpkov K; Gao Y; Tretiakova M; Liu YJ; Ulamec M; Takeuchi K; Agaimy A; Przybycin C; Magi-Galluzzi C; Fushimi S; Kojima F; Sibony M; Hang JF; Pan CC; Yilmaz A; Siadat F; Sugawara E; Just PA; Ptakova N; Hes O
Mod Pathol; 2020 Dec; 33(12):2564-2579. PubMed ID: 32467651
[TBL] [Abstract][Full Text] [Related]
24. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
[TBL] [Abstract][Full Text] [Related]
25. ALK Immunoexpression is Specific for Inflammatory Myofibroblastic Tumor Among Vulvovaginal Mesenchymal Neoplasms.
Bowman CJ; Medeiros F; Fadare O; Sangoi AR; Horvai AE; Devine WP; McCluggage WG; Rabban JT
Int J Gynecol Pathol; 2023 Jan; 42(1):1-10. PubMed ID: 35180768
[TBL] [Abstract][Full Text] [Related]
26. [Clinicopathological features of inflammatory myofibroblastic tumor].
Zhu Y; Ding Y; Song GX; Li X; Ding R; Fan QH; Gong QX
Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):194-200. PubMed ID: 33677881
[No Abstract] [Full Text] [Related]
27. Pseudosarcomatous myofibroblastic proliferations of the urinary bladder are neoplasms characterized by recurrent FN1-ALK fusions.
Acosta AM; Demicco EG; Dal Cin P; Hirsch MS; Fletcher CDM; Jo VY
Mod Pathol; 2021 Feb; 34(2):469-477. PubMed ID: 32908253
[TBL] [Abstract][Full Text] [Related]
28. [Inflammatory myofibroblastic tumors].
Sirvent N; Coindre JM; Pedeutour F
Ann Pathol; 2002 Dec; 22(6):453-60. PubMed ID: 12594387
[TBL] [Abstract][Full Text] [Related]
29. Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion.
Bennett JA; Wang P; Wanjari P; Diaz L; Oliva E
Genes Chromosomes Cancer; 2021 Dec; 60(12):822-826. PubMed ID: 34322931
[TBL] [Abstract][Full Text] [Related]
30. Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma.
Jiang Q; Tong HX; Hou YY; Zhang Y; Li JL; Zhou YH; Xu J; Wang JY; Lu WQ
Orphanet J Rare Dis; 2017 May; 12(1):97. PubMed ID: 28535796
[TBL] [Abstract][Full Text] [Related]
31. Assessment of ALK Fusions in Uncommon Inflammatory Myofibroblastic Tumors With ALK IHC Positivity but FISH-Equivocal Findings by Targeted RNA Sequencing.
Yao Q; Bai Q; Zhang X; Ji G; Chang H; Cai X; Yu L; Wang J; Zhu X; Zhou X
Arch Pathol Lab Med; 2022 Oct; 146(10):1234-1242. PubMed ID: 35041745
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory Myofibroblastic Tumor Driven by Novel
Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
[TBL] [Abstract][Full Text] [Related]
33. SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma.
Karanian M; Pissaloux D; Gomez-Brouchet A; Chevenet C; Le Loarer F; Fernandez C; Minard V; Corradini N; Castex MP; Duc-Gallet A; Blay JY; Tirode F
Am J Surg Pathol; 2020 May; 44(5):607-616. PubMed ID: 32187044
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory myofibroblastic tumor of the posterior mediastinum: an older adult case with anaplastic lymphoma kinase abnormalities determined using immunohistochemistry and fluorescence in situ hybridization.
Makimoto Y; Nabeshima K; Iwasaki H; Ishiguro A; Miyoshi T; Shiraishi T; Iwasaki A; Shirakusa T
Virchows Arch; 2005 Apr; 446(4):451-5. PubMed ID: 15778844
[TBL] [Abstract][Full Text] [Related]
35. Epithelioid inflammatory myofibroblastic sarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature.
Yu L; Liu J; Lao IW; Luo Z; Wang J
Diagn Pathol; 2016 Jul; 11(1):67. PubMed ID: 27460384
[TBL] [Abstract][Full Text] [Related]
36. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.
Coffin CM; Hornick JL; Fletcher CD
Am J Surg Pathol; 2007 Apr; 31(4):509-20. PubMed ID: 17414097
[TBL] [Abstract][Full Text] [Related]
38. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
39. Morphologic Overlap Between Inflammatory Myofibroblastic Tumor and IgG4-related Disease: Lessons From Next-generation Sequencing.
Taylor MS; Chougule A; MacLeay AR; Kurzawa P; Chebib I; Le L; Deshpande V
Am J Surg Pathol; 2019 Mar; 43(3):314-324. PubMed ID: 30451733
[TBL] [Abstract][Full Text] [Related]
40. EWSR1-SMAD3-rearranged Fibroblastic Tumor: An Emerging Entity in an Increasingly More Complex Group of Fibroblastic/Myofibroblastic Neoplasms.
Michal M; Berry RS; Rubin BP; Kilpatrick SE; Agaimy A; Kazakov DV; Steiner P; Ptakova N; Martinek P; Hadravsky L; Michalova K; Szep Z; Michal M
Am J Surg Pathol; 2018 Oct; 42(10):1325-1333. PubMed ID: 29957732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
